Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation-Reference-Cited by-同舟云学术

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation

Published:2020-05-08 Issue:11 Volume:63 Page:5956-5971
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Tng Jiahui¹,Lim Junxian¹²³^ORCID,Wu Kai-Chen¹²³,Lucke Andrew J.¹²,Xu Weijun¹,Reid Robert C.¹²³^ORCID,Fairlie David P.¹²³^ORCID

Affiliation:

1. Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia

2. Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia

3. Centre for Inflammation and Disease Research, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia

Funder

National Health and Medical Research Council

Australian Research Council

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00230

Reference95 articles.

1. Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease

2. Lysine acetylation in obesity, diabetes and metabolic disease